Antifungal adjuvants

Preserving and extending the antifungal arsenal

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.

Original languageEnglish (US)
Pages (from-to)198-210
Number of pages13
JournalVirulence
Volume8
Issue number2
DOIs
StatePublished - Feb 17 2017

Fingerprint

Fungal Drug Resistance
Mycoses
Plant Extracts
Peptides
Therapeutics
Research
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Parasitology
  • Microbiology
  • Immunology
  • Microbiology (medical)
  • Infectious Diseases

Cite this

Antifungal adjuvants : Preserving and extending the antifungal arsenal. / Butts, Arielle; Palmer, Glen; Rogers, Phillip.

In: Virulence, Vol. 8, No. 2, 17.02.2017, p. 198-210.

Research output: Contribution to journalReview article

@article{db703c9ca71a402192f8dcc0ebcf3b21,
title = "Antifungal adjuvants: Preserving and extending the antifungal arsenal",
abstract = "As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.",
author = "Arielle Butts and Glen Palmer and Phillip Rogers",
year = "2017",
month = "2",
day = "17",
doi = "10.1080/21505594.2016.1216283",
language = "English (US)",
volume = "8",
pages = "198--210",
journal = "Virulence",
issn = "2150-5594",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Antifungal adjuvants

T2 - Preserving and extending the antifungal arsenal

AU - Butts, Arielle

AU - Palmer, Glen

AU - Rogers, Phillip

PY - 2017/2/17

Y1 - 2017/2/17

N2 - As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.

AB - As the rates of systemic fungal infections continue to rise and antifungal drug resistance becomes more prevalent, there is an urgent need for new therapeutic options. This issue is exacerbated by the limited number of systemic antifungal drug classes. However, the discovery, development, and approval of novel antifungals is an extensive process that often takes decades. For this reason, there is growing interest and research into the possibility of combining existing therapies with various adjuvants that either enhance activity or overcome existing mechanisms of resistance. Reports of antifungal adjuvants range from plant extracts to repurposed compounds, to synthetic peptides. This approach would potentially prolong the utility of currently approved antifungals and mitigate the ongoing development of resistance.

UR - http://www.scopus.com/inward/record.url?scp=84982289348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982289348&partnerID=8YFLogxK

U2 - 10.1080/21505594.2016.1216283

DO - 10.1080/21505594.2016.1216283

M3 - Review article

VL - 8

SP - 198

EP - 210

JO - Virulence

JF - Virulence

SN - 2150-5594

IS - 2

ER -